Valeant Profit Rises Amidst Allergan Push

Jul 31 2014 | 11:41am ET

Valeant Pharmaceuticals International turned its second-quarter results announcement into another pitch for its $54 billion offer for rival Allergan Inc.

The Canadian company, which is working with Pershing Square Capital Management on its bid for Allergan, pointed to growth in almost all of its business lines as it announced higher profits and sales. And it said that it remains “focused on completing the Allergan transaction,” in spite of that company’s opposition to it.

Valeant has launched a hostile tender offer for Allergan, while Pershing Square seeks to oust the company’s board. Valeant said it planned to integrate Allergan in much the same way it merged with Bausch & Lomb.

That’s not likely to offer much comfort to Allergan, which has blasted Valeant as a serial acquirer with an unsustainable business strategy.


In Depth

Q&A: TCA Fund Management's Bob Press on Small-Cap Private Equity

Aug 25 2016 | 8:55pm ET

The emergence of private credit as a replacement for traditional bank financing...

Lifestyle

Kiawah: Island Reversal

Aug 24 2016 | 9:59pm ET

Looking for real estate investments but the typical real estate fare isn’t cutting...

Guest Contributor

Old Hill Partners: Embrace Illiquidity

Aug 9 2016 | 2:39pm ET

The age-old financial concept that higher yields are the result of higher risk and...